Multiple Internal Champions Can Propel Complex Licensing Deals, Pfizer Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Incyte deal is a model for negotiations involving multiple therapeutic areas, Pfizer exec tells licensing meeting.
You may also be interested in...
Millennium Shops Atherosclerosis Candidate After Positive Phase II
Biopharma seeks a partner before bringing the CCR2 antagonist into Phase III, firm tells “The Pink Sheet” DAILY.
Millennium Shops Atherosclerosis Candidate After Positive Phase II
Biopharma seeks a partner before bringing the CCR2 antagonist into Phase III, firm tells “The Pink Sheet” DAILY.
Incyte’s CCR5 Antagonist Has “Meaningful Advantages” Over Pfizer’s Maraviroc, Firm Says
Company says it is in active licensing discussions with “probably half a dozen” firms.